Insulet Corporation

pharma

Acton, MA · PODD · Public

Insulet is experiencing strong momentum with Q1 2026 revenue growth of 33.9% YoY and management forecasting 21-23% growth for 2026, driven by Omnipod 5 adoption and international expansion. The company is advancing its product pipeline with new data on Omnipod 6 and fully closed-loop AID systems while expanding sensor compatibility with Abbott's FreeStyle Libre 3 Plus.

Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical channels, though direct sales also occur. Geographically, Insulet serves markets spanning the United States, Canada, Europe, the Middle East, and Australia. Established in 2000, the corporation's headquarters are located in Acton, Massachusetts.

Employees

5,400

Mfg Plants

All Facilities

Activity

8/10

Type

Public